« Back
Home /
JH-RE-06

JH-RE-06

Item no.	HY-126214-100mg
Manufacturer	MedChem Express
CASRN	1361227-90-8
Amount	100 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 25 mg 50 mg 5 mg
Specific against	other
Purity	99.81
Citations	[1]Wojtaszek JL, et al. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 Jun 27;178(1):152-159.e11.<br/>[2]REV1-POLς Inhibition Enhances Cisplatin-Induced Cytotoxicity. Cancer Discov. 2019 Aug;9(8):OF17.
Smiles	O=C1C(C(CC(C)C)=O)=C(NC2=C(Cl)C=C(Cl)C=C2)NC3=C1C([N+]([O-])=O)=CC=C3Cl
Available
Product Description	JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy[1][2].
StorageTemperature	-20°C, 3 years (Powder)
Shipping	Blue Ice
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	468.72
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 5 mg/mL (ultrasonic)
Target	DNA/RNA Synthesis
Manufacturers Target	DNA/RNA Synthesis
Manufacturers Pathway	Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Request delivery time